On July 10, Akeso Bio rose 4.38% in regular trading, trading at HK$99.1/share, with turnover of HK$270 million.

On the news front, innovative drug payment reform continues to serve as a catalyst. The National Healthcare Security Administration previously released preliminary review results for the medical insurance directory, with the dual-track \"medical insurance + commercial insurance\" negotiation entering substantive implementation. New mechanisms including a pre-application system and 8-year price protection are simultaneously being rolled out, providing stable policy expectations for innovative drug commercialization. All indications of Akeso Bio's five self-developed new drugs have been included in the national medical insurance, and its new drug Qiyoukang has completed its first nationwide shipment, expected to accelerate market penetration.

Within the Biotechnology sector, the overall sector showed strength. Among individual stocks, REMEGEN up 5.06%, INNOVENT BIO up 4.11%, PEGBIO CO-B up 34.54%, 3SBIO up 2.06%, BEIGENE up 2.03%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)